Javitt Jonathan C 4
4 · NRX Pharmaceuticals, Inc. · Filed Dec 9, 2022
Insider Transaction Report
Form 4
Javitt Jonathan C
DirectorChairman and Chief Scientist10% Owner
Transactions
- Sale
Common Stock, par value $0.001 per share
2022-12-07$1.00/sh−400,000$400,000→ 12,899,997 total(indirect: By Trust)
Holdings
- 146,332
Common Stock, par value $0.001 per share
- 1,422,000(indirect: By Trust)
Common Stock, par value $0.001 per share
Footnotes (3)
- [F1]Private sale pursuant to an option granted by the Reporting Person in 2017 in support of a financing for NeuroRx, Inc. Purchaser has agreed to hold the shares for a period of one year.
- [F2]Held by the Jonathan Javitt Living Trust. The Reporting Person is a trustee of the Trust.
- [F3]Held by the Javitt 2012 Irrevocable Dynasty Trust. The Reporting Person is the grantor of the Trust.